

PharmAust Raises \$2.5m via Placement

- PharmAust raises \$2.5 million through an oversubscribed placement to institutional and sophisticated investors
- A total of \$2.4 million was placed to institutional and sophisticated investors while directors of the Company have subscribed for an additional \$0.104 million, subject to shareholder approval
- Offer price of 8 cents per new share represents a 20% discount to the 30-Day VWAP
- Placement funds will be used for the preparation for upcoming human trials, further manufacture of additional MPL tablets for human and canine trials and to strengthen working capital

3 May 2023: PharmAust Limited, (ASX: PAA & PAAO), a clinical stage biotechnology company, is pleased to announce it has received binding commitments to raise approximately \$2.5 million through an oversubscribed Placement.

The Placement will see the Company issue up to 30 million new shares at an issue price of \$0.08 per share (“Placement Shares”), each with a 1:2 free attaching option exercisable at \$0.15 with an expiry of 30 April 2026 (“Options”).

The strategic Placement was granted to a German and a Singaporean fund management institution. Remaining shares from the Placement went to Australian sophisticated investors including existing eligible shareholders.

In addition, directors of PAA have subscribed for an additional 1.3m shares to raise up to \$104,000, subject to Shareholder approval at a general meeting to be held at a date to be announced shortly.

PharmAust Executive Chairman Dr Roger Aston said “We are delighted with the outcome to the Placement, which has secured interest from new investors who recognise the value in the company. Proceeds will be used to fund the preparation for upcoming human trials, further manufacture of additional MPL tablets for human and canine trials and to strengthen working capital.”

PLACEMENT DETAILS

The issue price of \$0.08 represented a 20% discount to PAA’s closing share price on Friday, 28 April 2023 of \$0.10 and a 20% discount to the 30-day volume-weighted average price (VWAP) of \$0.10. The Placement Shares will rank equally with the Company’s existing shares. Settlement of the Placement is expected to be completed on 8 May 2023.

The Placement has been conducted pursuant to the Company’s existing Placement capacity under ASX Listing Rule 7.1. Up to a total of 30,000,000 new shares and 15,000,000 of new Options will be issued under Listing Rule 7.1.

Baker Young Limited acted as lead manager to the Placement.

This announcement is authorised by the Board.

Enquiries:

Anusha Aubert
Investor Relations
investorenquiries@pharmaust.com

P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com



About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated \$3.4 million in sales of goods & services in FY 2022.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.